CL2018003109A1 - Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. - Google Patents
Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos.Info
- Publication number
- CL2018003109A1 CL2018003109A1 CL2018003109A CL2018003109A CL2018003109A1 CL 2018003109 A1 CL2018003109 A1 CL 2018003109A1 CL 2018003109 A CL2018003109 A CL 2018003109A CL 2018003109 A CL2018003109 A CL 2018003109A CL 2018003109 A1 CL2018003109 A1 CL 2018003109A1
- Authority
- CL
- Chile
- Prior art keywords
- benzoimidazol
- hydroxy
- acrylamide
- diethylamino
- butyl
- Prior art date
Links
- 239000002131 composite material Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330673P | 2016-05-02 | 2016-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003109A1 true CL2018003109A1 (es) | 2019-04-26 |
Family
ID=60203321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003109A CL2018003109A1 (es) | 2016-05-02 | 2018-10-31 | Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10626092B2 (enExample) |
| EP (2) | EP3939966A1 (enExample) |
| JP (1) | JP2019514905A (enExample) |
| KR (1) | KR20190005904A (enExample) |
| CN (1) | CN109414425A (enExample) |
| AR (1) | AR108257A1 (enExample) |
| AU (1) | AU2017261218A1 (enExample) |
| BR (1) | BR112018072439A2 (enExample) |
| CA (1) | CA3022011A1 (enExample) |
| CL (1) | CL2018003109A1 (enExample) |
| CO (1) | CO2018012941A2 (enExample) |
| EA (1) | EA201892341A1 (enExample) |
| ES (1) | ES2886495T3 (enExample) |
| IL (1) | IL262578A (enExample) |
| MA (1) | MA44880A (enExample) |
| MX (1) | MX382095B (enExample) |
| PH (1) | PH12018502296B1 (enExample) |
| SG (1) | SG11201809471UA (enExample) |
| TW (1) | TW201741286A (enExample) |
| WO (1) | WO2017192451A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018157741A1 (zh) * | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | Sb-939的盐的晶型及其制备方法和用途 |
| US11465974B2 (en) | 2017-12-19 | 2022-10-11 | Assia Chemical Industries Ltd. | Crystalline polymorphs of Pracinostat and Pracinostat salts |
| WO2019149262A1 (zh) * | 2018-02-05 | 2019-08-08 | 苏州科睿思制药有限公司 | Sb-939的晶型及其制备方法和用途 |
| US20230159468A1 (en) | 2020-04-22 | 2023-05-25 | Macfarlan Smith Limited | Novel forms of pracinostat dihydrochloride |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2291749A1 (fr) | 1974-11-20 | 1976-06-18 | Delalande Sa | Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique |
| ATE198601T1 (de) | 1992-05-20 | 2001-01-15 | Merck & Co Inc | Ester derivate von 4-aza-steroiden |
| SE9804212D0 (sv) | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
| ID30439A (id) | 1999-01-13 | 2001-12-06 | Warner Lambert Co | Benzoheterosiklus dan penggunaannya sebagai penghambat mek |
| US6329380B1 (en) | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| EP1206265B1 (en) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| IL147150A0 (en) | 1999-07-16 | 2002-08-14 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| ATE250932T1 (de) | 1999-07-16 | 2003-10-15 | Warner Lambert Co | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer |
| GB9919558D0 (en) | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
| KR20100035666A (ko) | 1999-11-23 | 2010-04-05 | 메틸진 인크. | 히스톤 디아세틸라제의 억제제 |
| CZ20013424A3 (cs) | 1999-12-27 | 2002-02-13 | Japan Tobacco Inc. | Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva |
| US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1332131A2 (en) | 2000-11-07 | 2003-08-06 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| WO2008108741A1 (en) * | 2007-03-07 | 2008-09-12 | S*Bio Pte Ltd | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| JP2005517007A (ja) | 2002-02-07 | 2005-06-09 | アクシス・ファーマスーティカルズ | ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート |
| WO2003077855A2 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| WO2003087089A1 (en) | 2002-04-16 | 2003-10-23 | Teijin Limited | Piperidine derivatives having ccr3 antagonism |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US7151096B2 (en) | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| KR101127201B1 (ko) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
| US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| WO2005065681A1 (en) | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer |
| WO2006101456A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors |
| AU2006201177B2 (en) * | 2005-09-08 | 2012-06-14 | Mei Pharma, Inc. | Heterocyclic compounds |
| EP1937650B1 (en) * | 2005-09-08 | 2011-06-15 | S*BIO Pte Ltd | Heterocyclic compounds |
| PT2914254T (pt) * | 2012-10-30 | 2020-04-02 | Mei Pharma Inc | Terapias de combinação para tratar cancros quimiorresistentes |
-
2017
- 2017-04-28 AR ARP170101104A patent/AR108257A1/es unknown
- 2017-05-01 BR BR112018072439-4A patent/BR112018072439A2/pt not_active IP Right Cessation
- 2017-05-01 ES ES17793075T patent/ES2886495T3/es active Active
- 2017-05-01 US US16/098,435 patent/US10626092B2/en not_active Expired - Fee Related
- 2017-05-01 AU AU2017261218A patent/AU2017261218A1/en not_active Abandoned
- 2017-05-01 EP EP21178272.7A patent/EP3939966A1/en not_active Withdrawn
- 2017-05-01 EA EA201892341A patent/EA201892341A1/ru unknown
- 2017-05-01 CA CA3022011A patent/CA3022011A1/en not_active Abandoned
- 2017-05-01 MX MX2018013349A patent/MX382095B/es unknown
- 2017-05-01 EP EP17793075.7A patent/EP3452035B1/en active Active
- 2017-05-01 WO PCT/US2017/030414 patent/WO2017192451A1/en not_active Ceased
- 2017-05-01 CN CN201780041511.XA patent/CN109414425A/zh active Pending
- 2017-05-01 MA MA044880A patent/MA44880A/fr unknown
- 2017-05-01 SG SG11201809471UA patent/SG11201809471UA/en unknown
- 2017-05-01 KR KR1020187034681A patent/KR20190005904A/ko not_active Abandoned
- 2017-05-01 JP JP2018555958A patent/JP2019514905A/ja active Pending
- 2017-05-02 TW TW106114551A patent/TW201741286A/zh unknown
-
2018
- 2018-10-24 IL IL262578A patent/IL262578A/en unknown
- 2018-10-29 PH PH12018502296A patent/PH12018502296B1/en unknown
- 2018-10-31 CL CL2018003109A patent/CL2018003109A1/es unknown
- 2018-11-29 CO CONC2018/0012941A patent/CO2018012941A2/es unknown
-
2020
- 2020-03-09 US US16/813,230 patent/US20200317621A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190005904A (ko) | 2019-01-16 |
| IL262578A (en) | 2018-12-31 |
| US20200317621A1 (en) | 2020-10-08 |
| EA201892341A1 (ru) | 2019-05-31 |
| BR112018072439A2 (pt) | 2019-02-19 |
| US10626092B2 (en) | 2020-04-21 |
| CA3022011A1 (en) | 2017-11-09 |
| CO2018012941A2 (es) | 2018-12-28 |
| US20190152923A1 (en) | 2019-05-23 |
| ES2886495T3 (es) | 2021-12-20 |
| SG11201809471UA (en) | 2018-11-29 |
| MX382095B (es) | 2025-03-13 |
| EP3452035A4 (en) | 2019-09-25 |
| JP2019514905A (ja) | 2019-06-06 |
| CN109414425A (zh) | 2019-03-01 |
| PH12018502296B1 (en) | 2022-04-06 |
| AR108257A1 (es) | 2018-08-01 |
| AU2017261218A1 (en) | 2018-11-29 |
| TW201741286A (zh) | 2017-12-01 |
| EP3452035B1 (en) | 2021-07-07 |
| MX2018013349A (es) | 2019-02-20 |
| MA44880A (fr) | 2021-03-17 |
| PH12018502296A1 (en) | 2019-07-08 |
| EP3939966A1 (en) | 2022-01-19 |
| EP3452035A1 (en) | 2019-03-13 |
| WO2017192451A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2019001744A1 (es) | Derivados de benzoxazol como inmunomoduladores. | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2019008783A2 (es) | Compuestos dinucleotidos ciclicos para el tratamiento del cancer | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CO2019013016A2 (es) | Inhibidores pirazólicos de magl | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| CO2019004945A2 (es) | Inhibidores de la magl | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CO2019005059A2 (es) | Inhibidores de magl | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| CO2019005038A2 (es) | Inhibidores de magl | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| CL2018001085A1 (es) | Derivados de indolin-2-ona | |
| CR20160529A (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| DOP2016000161A (es) | Ureas asimétricas p- sustituidas y usos médicos de las mismas. | |
| CO2018012941A2 (es) | Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| MX2018004868A (es) | Derivados de la pirrolidina. | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades |